AI Proteins designs de novo miniprotein medicines engineered from first principles for precise therapeutic function. This next-generation biologic modality offers high control over selectivity, stability, and pharmacokinetics, minimizing off-target effects and unwanted immune responses. The platform enables the rapid synthesis and validation of potent, programmable, and safe treatments tailored to specific patient needs.
Funding
$5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The development of protein-based therapeutics is often limited by challenges in achieving high specificity, durability, and cost-effectiveness. Traditional protein engineering approaches can be slow and may not fully exploit the potential of synthetic biology and artificial intelligence for creating optimized drug candidates.
Solution
AI Proteins is developing a platform for designing and engineering synthetic miniprotein therapeutics. The company combines synthetic biology, robotics, automation, and artificial intelligence to create highly specific and durable medicines. Their de novo design capabilities allow for complete structural control, enabling the creation of patentable miniproteins that combine characteristics of small molecules and biologics. The platform facilitates rapid design, construction, and development of miniprotein medicines with potential for various administration options.
Target Audience
The primary focus is on developing therapeutics for oncology, while also exploring partnerships in inflammation, metabolic diseases, and other therapeutic areas.
Features
- Proprietary platform integrating synthetic biology, robotics, and AI for miniprotein design
- De novo design capabilities for complete structural control and customizable therapeutic characteristics
- Ability to create miniproteins with high specificity and durability
- Potential for various administration options
- Identification of novel candidates against high-value therapeutic targets